# Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

> **NCT03566823** · PHASE3 · TERMINATED · sponsor: **Shire** · enrollment: 34 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Ontamalimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03566823
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-17
- **Primary completion:** 2020-08-18
- **Final completion:** 2020-08-18
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03566823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03566823, "Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03566823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*